Necitumumab

奈妥木单抗

Report date: 2026/05/20 20:02:01

Base Information

Drug NameNecitumumab
Drug Alias Name奈昔木单抗奈西妥木单抗PortrazzaIMC-11F8LY-3012211
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonists
TargetsEpidermal growth factor receptor erbB1
Therapy Area/IndicationsSolid tumoursNeoplasm MetastasisCarcinoma, Non-Small-Cell Lung +[5] 
Global Approved IndicationsCarcinoma, Non-Small-Cell Lung
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2015/11/24
Country/TerritoryBelgiumCanadaUnited States +[30] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesEli Lilly And CompanyEli Lilly And Co (Ireland) LtdMerck KGaA, Darmstadt, Germany +[4] 
Inactive CompaniesEli Lilly Nederland BV
Active IndicationsCarcinoma, Non-Small-Cell Lung
Inactive IndicationsSolid tumoursNeoplasm MetastasisColorectal Neoplasms +[4] 

Other Information

ATC CodeL01XC22
Related LinksWikipediaDrugBankKEGG